Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
137.3 EUR | -0.54% | +0.53% | -3.06% |
01:27pm | Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex | MT |
01:26pm | Stock Futures Decline as Traders Await More Earnings; Asia, Europe Churn | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 4.15 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.06% | 363B | - | ||
+61.53% | 848B | C+ | ||
+33.43% | 627B | B | ||
+15.06% | 318B | B- | ||
+9.18% | 299B | C+ | ||
+12.39% | 234B | A+ | ||
+16.17% | 225B | B- | ||
+15.67% | 179B | C+ | ||
+2.47% | 167B | C+ | ||
+2.24% | 125B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson